Shenzhen Salubris Pharma acquired China rights to a dual glucagon-like peptide-1 receptor/glucagon receptor agonist from D&D Pharmatech of South Korea. Salubris, which will make a $4 million upfront payment, will develop the candidate for obesity, nonalcoholic steatohepatitis (NASH) and diabetes. It will also pay milestones and double digit royalties on sales. The candidate, DD01, is currently being tested in a US Phase I clinical trial. In preclinical models, DD01 was more effective than an approved GLP-1R agonist.  More details.... Share this with colleagues: // //